Why Attend
With the neurological drug market now worth $86 billion, and the FDA set to reach a decision on Biogen’s Acudanimib in Spring, whether you’re focused on oncology, Alzheimer’s or ALS, it’s an exciting time to be targeting misfolding diseases.
Though there are currently no therapies and cures in this area of drug discovery due to several unmet drug discovery needs. The inaugural Targeting Protein Misfolding Congress will bring together academic and industry leaders, such as Anavex, Ionis Pharmaceuticals, Wren Therapeutics, Arizona State University and University of Florida, who are building platforms to identify and validate targets in protein misfolding diseases and intrinsically disordered proteins to combat these challenges:
- The lack of appropriate disease models, physiological assays and blood biomarkers to evaluate translation aspects and target engagement.
- Delivery mechanisms to deliver small molecules and biologics across the blood brain barrier.
- Determining the true drivers and toxic species in protein misfolding diseases.
- Mapping the druggable hotspots on protein aggregates and intrinsically disordered proteins to target with small molecules.
Key outcomes this year include:
- Improve pre-clinical predictability by learning what disease models are now considered best practice with Beth Hoffman, Founder and CEO, Origami Therapeutics and understand how Pfizer develops physiologically relevant assays for phenotypic screening.
- Understand the underlying chemical biology of protein aggregation and the drivers behind misfolding diseases to help inform your target validation with Peter Lansbury, CSO, Lysosomal Therapeutics
- Learn about the latest developments in delivery of biologics across the blood brain barrier as well as viral delivery advancements with Laura Ranum, Professor, University of Florida
- Target your aggregate of choice after hearing Behnam Nabet, Research Fellow, Dana Farber Cancer Institute discuss novel approaches involving degradation
Speakers
Johanne Kaplan
Abhishek Singharan
Tiago Outeiro
Jack Rogers
Alberto Perez
Laura Ranum
Peter Lansbury
Beth Hoffman
Gene Yeo
Hien Zhao
Alexander Scheer
Chris Missling
Rick Morimoto
Michele Vendruscolo
Judith Frydman
Gergely Toth
Mark Reed
Marcia Taylor
Dr. Marcia Taylor is the Vice President in charge of Research at Treventis Corporation. She has enabled key assays in the discovery of small molecules to prevent formation of toxic oligomers. She has led her team through small molecule synthesis, activity, DMPK, preclinical, and toxicity studies on the road to a disease modifying treatment for diseases of protein misfolding. Dr. Taylor received a PhD in Biochemistry and Molecular Biology from Dalhousie University.
Behnam Nabet
Sponsors
Media Partners
Drug Discovery World
Website: https://www.ddw-online.com/
Drug Discovery World is the multi-platform global voice for the drug discovery community. From research stage to clinical trials the brand covers the scientific and commercial process involved in getting a drug to market–research, target identification and validation, drug molecule identification, lead molecule optimisation, pre-clinical research, clinical trial authorisation and application, and clinical trials phase I and II. DDW readers learn how to turn science into business.
DDW is available as a quarterly printed publication, online and as a free-to-download app containing trusted content as well as premium hand-picked intelligence for anyone involved in drug discovery and development. Readers can also sign up for our free weekly e-newsletter.
From bench through to boardroom DDW offers commercial insight for researchers, scientists and decision-makers involved in drug discovery and development. We cover the latest news and events in the global pharmaceutical, biopharmaceutical and biotech sectors, as well as the technology and processes to help create vaccines, therapeutics and drugs.
Partner With Us
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact [email protected].
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
The Agenda
Please download our 2021 agenda to find out more information about the congress including the main topics of discussion for the three days and preview lineup of speakers.
Download Full Agenda
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.